Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1540-1551
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1540
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1540
Figure 2 Five-year overall survival rate and recurrence free survival rate of all patients, Siewert type II gastroesophageal junction patients, and Siewert type III gastroesophageal junction patients in chemoradiotherapy group and chemotherapy group.
A: Five-year overall survival rate in chemoradiotherapy (CRT) group and chemotherapy (CT) group; B: Five-year recurrence free survival rate in CRT group and CT group.
- Citation: Kang WZ, Shi JM, Wang BZ, Xiong JP, Shao XX, Hu HT, Jin J, Tian YT. Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection. World J Gastrointest Oncol 2022; 14(8): 1540-1551
- URL: https://www.wjgnet.com/1948-5204/full/v14/i8/1540.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i8.1540